Rossari Biotech Ltd IPO - Details
About the company
Rossari Biotech is one of the leading specialty chemical manufacturing companies in India. It provides customized solutions to the apparel, animal & poultry feed, and FMCG industries by offering a diversified product portfolio.
IPO Dates ,Types & Price details
IPO ISSUE PERIOD
13-Jul-2020 to 15-Jul-2020
Listing on BSE & NSE
IPO Size
(Rs.444.15 – 446.25 crore)
10,500,000 shares
Price Range
Rs. 423 -425 Per Share
IPO Type
100% Book Building
Retail Portion : 35%
BID LOT
35 Shares and in multiples of 35.
Minimum Amount: ₹14,805
Face Value
Rs. 2
(IN Rs. CRORE)
Financial Performance
Valuation of Rossari Biotech
Earnings Per Share (EPS): INR13.42
Price/Earnings (PE ratio): 33.81 Market Cap : 2207 Crore
Return on Net Worth (RONW): 31.79%
Net Asset Value (NAV): INR56.48 per share
Contact details
IPO Registrar
Link Intime India Private Ltd
C 101, 247 Park, L.B.S.Marg,
Vikhroli (West), Mumbai – 400083
Phone: +91-22-4918 6270
Email: rossaribio.ipo@linkintime.co.in
Website: http://www.linkintime.co.in
IPO Lead Managers
- Axis Capital Limited
- ICICI Securities Limited
Company Address
Rossari Biotech Ltd
201 A – B, 2nd Floor,
Akruti Corporate Park, L.B.S. Marg,
next to GE Gardens, Kanjurmarg (W), Mumbai 400 079
Phone: +91 22 6123 3800
Email: cs@rossarimail.com Website: www.rossari.com
Rossari Biotech IPO Subscription Details
Category | No of Shares offered | DAY 1 | DAY 2 | DAY 3 |
---|---|---|---|---|
Qualified Institutional Buyers(QIBs) | 23,35,294 | 2,27,955 | 49,15,015 | 13,47,10,520 |
Non Institutional Investors (NIIs) | 17,51,470 | 1,38,040 | 5,71,515 | 22,73,28,360 |
Retail Individual Investors(RIIs) | 40,86,765 | 17,05,830 | 39,49,050 | 1,03,18,980 |
Total | 81,73,530 | 20,71,825 | 94,35,580 | 37,23,57,860 |
Subscription Times | - | 0.25 | 1.15 | 45.56 |
Post Subscription Details
Finalisation of Allotment
20-Jul-2020
Click on this link to get allotment status.
Initiation of refunds
21-Jul-2020
Transfer of shares to demat accounts
22-Jul-2020
Listing Date
23-Jul-2020
Opening Price on NSE
670.00
Closing Price on NSE
741.65
AUTHOR’S Final Note :
Considering the PAT growth YoY, IPO looks attractive. But the PE ratio greater than 30, IPO comes under High priced band.
For the High risk Investors, IPO is definitely worth a risk to apply and look for Listing gains.
Read here on How to apply IPO via Zerodha ?
For Low risk investors, Avoid this IPO in this turbulent market.
Grey Market Premium :
GMP was around 130 which is good indicator for the decent Listing gain.
What is Grey Market Premium and how it works
Additional Reading :
Nifty Monthly Returns – Year
- Jeysivaa
- 01 January 2022
Nifty 50 is benchmark index of an Indian stock market. Please see below graph for the Nifty and it’s weightage.
Nifty Monthly Returns – June
- Jeysivaa
- 30 June 2021
Nifty 50 is benchmark index of an Indian stock market. Please see below graph for the Nifty and it’s weightage.
Sensex 30 Companies and its
- Jeysivaa
- 12 June 2021
The Sensex (orBSE30) index is a well-diversified 30 major companies in the index reflecting overall market conditions whereas Nifty50 have
Nifty Monthly Returns – May
- Jeysivaa
- 01 June 2021
Nifty 50 is benchmark index of an Indian stock market. Please see below graph for the Nifty and it’s weightage.
NIFTY 50 Index Companies and
- Jeysivaa
- 05 May 2021
The NIFTY 50 index is a well-diversified 50 companies index reflecting overall market conditions. It is used for a variety
Disclaimer: “We are an educational forum for analysing, learning & discussing general and generic information related to stocks, investments and strategies. No content on the site constitutes – or should be understood as constituting – a recommendation to enter in any securities transactions or to engage in any of the investment strategies presented in our site content. We do not provide personalised recommendations or views as to whether a stock or investment approach is suited to the financial needs of a specific individual.”
“All types of content provided here are the bloggers personal views. It should not be considered as financial advice. You should consult with your own financial advisor before using any information provided here.”